<DOC>
	<DOCNO>NCT01220297</DOCNO>
	<brief_summary>GVHD prophylaxis sirolimus mycophenolate mofetil patient undergo match related allogeneic transplant acute chronic leukemia , MDS , high risk NHL HL</brief_summary>
	<brief_title>Sirolimus &amp; Mycophenolate Mofetil GVHD Prophylaxis Myeloablative , Matched Related Donor HCT</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Disease Categories ( participant one follow ) AML , age 2 60 year beyond 2nd remission relapsed/refractory disease AML , age 5160 year age , first subsequent remission relapsed/refractory disease AML multilineage dysplasia ALL , age 2 60 year beyond 2nd remission relapsed/refractory disease ALL , age 51 60 year first subsequent remission relapsed/refractory disease CML Beyond 2nd chronic phase blast crisis MDS ; Includes World Health Organization classification refractory anemia excess blasts1 ( RAEB1 ) , RAEB2 therapyrelated MDS Myeloproliferative disorder ; MDS poor longterm survival include myeloid metaplasia myelofibrosis High risk NHL first remission Relapsed refractory NHL HL beyond first remission Males females ethnic background 2 60 year age Karnofsky Performance Status &gt; = 70 % Lansky performance status &gt; 70 % patient &lt; 16 year age . Matched related donor identify 6/6 HLAA , B DRB1 Willingness take oral medication transplantation period Ability understand willingness sign write informed consent document Prior myeloablative allogeneic autologous HCT HIV infection Pregnant lactating female Evidence uncontrolled active infection Organ Dysfunction Serum creatinine &gt; 1.5 mg/dL 24 hour creatinine clearance &lt; 50 ml/min Direct bilirubin , ALT AST &gt; 2 x ULN In adult DLCO &lt; 60 % predicted child room air oxygen saturation &lt; 92 % In adult , leave ventricular ejection fraction &lt; 45 % child , shorten fraction &lt; 26 % Fasting Cholesterol &gt; 300 mg/dL Triglycerides &gt; 300 mg/dL lipidlowering agent . Patients receive investigational drug unless clear PI . Patients prior malignancy except basal cell carcinoma treat carcinoma insitu . Cancer treat curative intent &gt; 5 year allow . Cancer treat curative intent &lt; = 5 year allow PI approval .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>